Marksans Pharma Ltd
NSE: MARKSANS BSE: 524404
₹172.95
(-0.64%)
Wed, 18 Mar 2026, 07:16 am
Market Cap78.85B
PE Ratio21.75
Dividend0.46
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1992
- TASC Industries (India) Ltd. was incorporated as a Public Limited Company under the Companies Act 1956.
- The company obtained the certificate of commencement of business.
2005
- The company changed its name from Tasc Pharmaceuticals Ltd. to Marksans Pharma Ltd.
- Marksans acquired Nova Australasia Pty Ltd., an Australian marketing company.
2006
- The Board of Directors of the Company appointed Mr V Nagaraj as Additional as well as Whole Time Director (marketing) of the Company.
2008
- The company split its face value from Rs10/- to Rs1/-.
- The Registered Office of the Company was shifted from 601-622, Chintamani Plaza, Mohan Studio Compound, Andheri-Kurla Road, Andheri (E), Mumbai 400 099 to 21st Floor, Lotus Business Park, Off New Link Road, Andheri (W), Mumbai 400 053.
- Marksans acquired UK's Hale Group along with its subsidiary company Bell, Sons & Co. (Druggists) Ltd.
- Marksans acquired Relonchem Ltd in August 2008.
2009
- Marksans Pharma Limited announced USFDA approval of generic Ibuprofen Capsules (Liquid Filled), 200 mg for Advil Liqui - Gels 200 mg.
2010
- The company entered into a Business Transfer Agreement with Kores (India) Limited.
- The Registered Office of the Company was shifted from 21st Floor, Lotus Business park, Off New Link Road, Andheri (W), Mumbai - 400053 to 11th Floor, Lotus Business Park, Off New Link Road, Andheri (W), Mumbai - 400053.
2011
- Dr. Balwant Shankarrao Desai was appointed as a Whole-time Director of the Company.
2012
- Mr. Ajay S. Joshi was appointed as a Director of the Company.
2013
- Marksans Pharma Ltd appointed Mr. Naresh Balwant Wadhwa as an additional Director of the Company.
2014
- Marksans Pharma Ltd recommended dividend of 10% which is Rs. 0.10 per equity share of Rs. 1/- each face value.
- The Registered office of the company was shifted to 11th Floor, 'GRANDEUR', Opp. Gundeecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai -400053.
2015
- Marksans Pharma gained on acquiring Time-Cap Laboratories.
2016
- Marksans Pharma gets USFDA nod for Paricalcitol capsules.
- Marksans Pharma gets USFDA nod for diabetes treatment drug.
- Marksans Pharma bags USFDA approval for Loratadine.
2017
- Marksans Pharma Goa plant received UK MHRA approval.
- Marksans Pharma received certificate of GMP Compliance of a Manufacturer from Australian government, Department of Health, Therapeutic Goods Administration.
2021
- Marksans Pharma received USFDA approval for Acetaminophen ER Tablets.
2022
- The company completed the process of acquiring 100% share capital of Access Healthcare for Medical Products LLC based in Dubai, UAE.
- Marksans Pharma received USFDA approval for Cetirizine Hydrochloride Tablets.
- Marksans Pharma received UK MHRA approval for Bells Healthcare All in One Oral Solution.
2023
- Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited received Marketing Authorisation for Cyanocobalamin 50mg film coated tablets.
- Marksans Pharma completed the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India.
- Marksans Pharma received UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution.
2024
- Marksans Pharma Limited receives USFDA approval for Loratadine Tablets USP 10mg.
- US FDA Inspection at Marksans Pharma's manufacturing facility located at Verna, Goa was successfully closed.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800